Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12503324 | 0.88 | PPARA (0.60) | PLA2G4BPPARGPPARATSHRPSEN1 | |
| SCHEMBL1697010 | 0.87 | PPARA (0.56) | PLA2G4BPPARGPPARAMTNR1ATSHR | |
| SCHEMBL368053 | 0.85 | PPARA (0.44) | PLA2G4BPPARGPPARATSHRPSEN1 | |
| SCHEMBL370943 | 0.84 | PPARA (0.49) | PPARGPPARAMTNR1APSEN1PSEN2 | |
| SCHEMBL343934 | 0.84 | THRB (0.56) | PLA2G4BTHRBNR1H4 | |
| SCHEMBL12503223 | 0.81 | MAPK1 (0.42) | PPARGPPARANR1H4MTNR1ATSHR | |
| SCHEMBL5434776 | 0.76 | PLA2G4B (0.81) | PLA2G4BPPARGPPARAPTPN7TSHR | |
| SCHEMBL15427588 | 0.75 | THRB (0.55) | THRBNR1H4PSEN1PSEN2APH1B | |
| SCHEMBL371036 | 0.75 | PSEN1 (0.44) | PPARGPPARATHRBNR1H4TSHR | |
| SCHEMBL15427384 | 0.74 | THRB (0.60) | THRBNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633220-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012003145-A2 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | PLA2G4B 701/4885PPARG 558/4885PPARA 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.